Akihiko Koyama
Overview
Explore the profile of Akihiko Koyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rizoska B, Zachrisson O, Appelkvist P, Bostrom E, Bjorklund M, Rachalski A, et al.
Mol Cell Neurosci
. 2024 Jun;
130:103950.
PMID: 38901655
Amyloid beta (Aβ) peptides, which aggregate to form neocortical plaques in Alzheimer's disease, exist in states that range from soluble monomers and oligomers/protofibrils to insoluble fibrillar amyloid. The present study...
2.
Vilizzi L, Piria M, Pietraszewski D, Giannetto D, Flory S, Herczeg G, et al.
Sci Total Environ
. 2024 Jan;
917:170475.
PMID: 38296092
Under the increasing threat to native ecosystems posed by non-native species invasions, there is an urgent need for decision support tools that can more effectively identify non-native species likely to...
3.
Koyama A, Inui R
Sci Rep
. 2024 Jan;
14(1):861.
PMID: 38195849
In the context of global climate change, monitoring focused on temperature and benthic animals in intertidal flats and the development of metrics to assess climate change and ecosystem responses are...
4.
Horie K, Salvado G, Barthelemy N, Janelidze S, Li Y, He Y, et al.
Nat Med
. 2023 Jul;
29(8):1954-1963.
PMID: 37443334
Aggregated insoluble tau is one of two defining features of Alzheimer's disease. Because clinical symptoms are strongly correlated with tau aggregates, drug development and clinical diagnosis need cost-effective and accessible...
5.
Horie K, Li Y, Barthelemy N, Gordon B, Hassenstab J, Benzinger T, et al.
Ann Neurol
. 2023 Feb;
93(6):1158-1172.
PMID: 36843330
Objective: Identifying cerebrospinal fluid measures of the microtubule binding region of tau (MTBR-tau) species that reflect tau aggregation could provide fluid biomarkers that track Alzheimer's disease related neurofibrillary tau pathological...
6.
Geerts H, Walker M, Rose R, Bergeler S, van der Graaf P, Schuck E, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Jan;
12(4):444-461.
PMID: 36632701
Antibody-mediated removal of aggregated β-amyloid (Aβ) is the current, most clinically advanced potential disease-modifying treatment approach for Alzheimer's disease. We describe a quantitative systems pharmacology (QSP) approach of the dynamics...
7.
McDade E, Cummings J, Dhadda S, Swanson C, Reyderman L, Kanekiyo M, et al.
Alzheimers Res Ther
. 2022 Dec;
14(1):191.
PMID: 36544184
Background: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The...
8.
Hayato S, Takenaka O, Sreerama Reddy S, Landry I, Reyderman L, Koyama A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Sep;
11(12):1578-1591.
PMID: 36165093
Lecanemab is a humanized immunoglobulin G1 monoclonal antibody that selectively binds to soluble Aβ aggregate species, while demonstrating low affinity for Aβ monomer. This article describes the population pharmacokinetic (PK)...
9.
Yamashita K, Miura M, Watanabe S, Ishiki K, Arimatsu Y, Kawahira J, et al.
Alzheimers Res Ther
. 2022 Jun;
14(1):86.
PMID: 35739591
Background: Clinicians, researchers, and patients alike would greatly benefit from more accessible and inexpensive biomarkers for neural β-amyloid (Aβ). We aimed to assess the performance of fully automated plasma Aβ...
10.
Swanson C, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai R, et al.
Alzheimers Res Ther
. 2022 May;
14(1):70.
PMID: 35598024
No abstract available.